AU2016214537B2 - 9H-pyrrolo-dipyridine derivatives - Google Patents
9H-pyrrolo-dipyridine derivatives Download PDFInfo
- Publication number
- AU2016214537B2 AU2016214537B2 AU2016214537A AU2016214537A AU2016214537B2 AU 2016214537 B2 AU2016214537 B2 AU 2016214537B2 AU 2016214537 A AU2016214537 A AU 2016214537A AU 2016214537 A AU2016214537 A AU 2016214537A AU 2016214537 B2 AU2016214537 B2 AU 2016214537B2
- Authority
- AU
- Australia
- Prior art keywords
- pyrrolo
- optionally substituted
- methyl
- dipyridine
- halogens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(cc1*)nc(*)c1-c1ccc(c2cnccc2[n]2)c2n1 Chemical compound Cc(cc1*)nc(*)c1-c1ccc(c2cnccc2[n]2)c2n1 0.000 description 9
- YJFDJTNGFPHWAM-UHFFFAOYSA-N CC1(C)OB(c2n[nH]c(C)c2)OC1(C)C Chemical compound CC1(C)OB(c2n[nH]c(C)c2)OC1(C)C YJFDJTNGFPHWAM-UHFFFAOYSA-N 0.000 description 1
- DINGZOCGMDSQHE-UHFFFAOYSA-N CNC(c(cc1)ncc1-c1ccc(c2cnccc2[nH]2)c2n1)=O Chemical compound CNC(c(cc1)ncc1-c1ccc(c2cnccc2[nH]2)c2n1)=O DINGZOCGMDSQHE-UHFFFAOYSA-N 0.000 description 1
- JHFJFJHQZAIQLE-UHFFFAOYSA-N CNC(c(cn1)ccc1Br)=O Chemical compound CNC(c(cn1)ccc1Br)=O JHFJFJHQZAIQLE-UHFFFAOYSA-N 0.000 description 1
- BQJQGNUGTXEDOF-UHFFFAOYSA-N CNC(c(cn1)ccc1[Sn](C)(C)C)=O Chemical compound CNC(c(cn1)ccc1[Sn](C)(C)C)=O BQJQGNUGTXEDOF-UHFFFAOYSA-N 0.000 description 1
- MFKBDJBBFKJRDS-UHFFFAOYSA-N CNC(c1ccc(-c2ccc(c(c([nH]3)c4)cnc4OC)c3n2)nc1)=O Chemical compound CNC(c1ccc(-c2ccc(c(c([nH]3)c4)cnc4OC)c3n2)nc1)=O MFKBDJBBFKJRDS-UHFFFAOYSA-N 0.000 description 1
- NCFMDIJKEYGCRD-UHFFFAOYSA-N COc1c[nH]nc1 Chemical compound COc1c[nH]nc1 NCFMDIJKEYGCRD-UHFFFAOYSA-N 0.000 description 1
- DZCDYZWUSHIPHQ-UHFFFAOYSA-N COc1c[n](-c(cc2)nc3c2c(ccnc2)c2[nH]3)nc1 Chemical compound COc1c[n](-c(cc2)nc3c2c(ccnc2)c2[nH]3)nc1 DZCDYZWUSHIPHQ-UHFFFAOYSA-N 0.000 description 1
- ZYIUFBZANBZCOW-UHFFFAOYSA-N C[Sn](C)(C)c(nc1)ccc1C(N)=O Chemical compound C[Sn](C)(C)c(nc1)ccc1C(N)=O ZYIUFBZANBZCOW-UHFFFAOYSA-N 0.000 description 1
- SBWXKXXPHSUKRY-UHFFFAOYSA-N ClC1=NC2C=Cc3ccncc3C2C=C1 Chemical compound ClC1=NC2C=Cc3ccncc3C2C=C1 SBWXKXXPHSUKRY-UHFFFAOYSA-N 0.000 description 1
- QCTHDAPPTWLTGR-UHFFFAOYSA-N Clc(cc1)nc2c1c(cncc1)c1[nH]2 Chemical compound Clc(cc1)nc2c1c(cncc1)c1[nH]2 QCTHDAPPTWLTGR-UHFFFAOYSA-N 0.000 description 1
- VZRAAQURGGLCMY-UHFFFAOYSA-N Clc1ccc(c(ccnc2)c2[nH]2)c2n1 Chemical compound Clc1ccc(c(ccnc2)c2[nH]2)c2n1 VZRAAQURGGLCMY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 | ||
| EP15153448.4 | 2015-02-02 | ||
| PCT/EP2016/051993 WO2016124508A1 (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016214537A1 AU2016214537A1 (en) | 2017-08-03 |
| AU2016214537B2 true AU2016214537B2 (en) | 2018-05-10 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016214537A Active AU2016214537B2 (en) | 2015-02-02 | 2016-01-29 | 9H-pyrrolo-dipyridine derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (enExample) |
| EP (1) | EP3253762B1 (enExample) |
| JP (1) | JP6579670B2 (enExample) |
| KR (1) | KR102621513B1 (enExample) |
| CN (1) | CN107207508B (enExample) |
| AU (1) | AU2016214537B2 (enExample) |
| BR (1) | BR112017016311A2 (enExample) |
| CA (1) | CA2973648C (enExample) |
| CL (1) | CL2017001923A1 (enExample) |
| DK (1) | DK3253762T3 (enExample) |
| EA (1) | EA036518B1 (enExample) |
| ES (1) | ES2875734T3 (enExample) |
| IL (1) | IL253381B (enExample) |
| MX (1) | MX378155B (enExample) |
| MY (1) | MY191590A (enExample) |
| SG (1) | SG11201705727TA (enExample) |
| WO (1) | WO2016124508A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100135235A (ko) | 2008-02-14 | 2010-12-24 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | 신경학적 기능이상을 검출하기 위한 조영제 |
| ES2875734T3 (es) * | 2015-02-02 | 2021-11-11 | UCB Biopharma SRL | Derivados de 9H-pirrolo-dipiridina |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| MX386900B (es) | 2016-07-22 | 2025-03-19 | Ac Immune S A Star | Compuestos para formacion de imagenes de agregados de proteinas tau. |
| MX375720B (es) * | 2016-09-09 | 2025-03-04 | Hoffmann La Roche | Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol. |
| AU2017367872B2 (en) * | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| SG11201911512SA (en) | 2017-06-02 | 2020-01-30 | Fujifilm Toyama Chemical Co Ltd | Agent for preventing or treating brain atrophy |
| US11666551B2 (en) | 2017-06-02 | 2023-06-06 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid β protein |
| RU2739199C1 (ru) * | 2017-06-02 | 2020-12-21 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Лекарственное средство для предотврашения или лечения таупатии |
| JPWO2018221728A1 (ja) | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
| RU2728717C1 (ru) | 2017-06-02 | 2020-07-30 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Средство для профилактики или лечения спиноцеребеллярной атаксии |
| US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| KR20200113234A (ko) * | 2018-01-24 | 2020-10-06 | 에이씨 이뮨 에스.에이. | 이미징 화합물을 제조하는 신규한 방법 |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| EP3743426A1 (en) * | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102498A1 (en) * | 2008-02-14 | 2009-08-20 | Siemens Medical Solutions Usa, Inc. | Novel imaging agents for detecting neurological dysfunction |
| WO2015052105A1 (en) * | 2013-10-08 | 2015-04-16 | F. Hoffmann-La Roche Ag | Diazacarbazole derivatives as tau-pet-ligands |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| ES2490867T3 (es) * | 2008-12-19 | 2014-09-04 | Bristol-Myers Squibb Company | Inhibidores de carbazol y carbolina quinasas |
| KR101609504B1 (ko) * | 2012-05-22 | 2016-04-05 | 일라이 릴리 앤드 캄파니 | 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제 |
| US20160115162A1 (en) | 2013-05-31 | 2016-04-28 | The General Hospital Corporation | Radiosynthesis of Tau Radiopharmaceuticals |
| WO2015010263A1 (en) * | 2013-07-24 | 2015-01-29 | Telefonaktiebolaget L M Ericsson(Publ) | Method and apparautus relating to reception of radio signals |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| ES2875734T3 (es) * | 2015-02-02 | 2021-11-11 | UCB Biopharma SRL | Derivados de 9H-pirrolo-dipiridina |
-
2016
- 2016-01-29 ES ES16702121T patent/ES2875734T3/es active Active
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 EA EA201791733A patent/EA036518B1/ru not_active IP Right Cessation
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/ja active Active
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/zh active Active
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/da active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en not_active Ceased
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 MX MX2017009505A patent/MX378155B/es unknown
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/pt not_active Application Discontinuation
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/ko active Active
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/es unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009102498A1 (en) * | 2008-02-14 | 2009-08-20 | Siemens Medical Solutions Usa, Inc. | Novel imaging agents for detecting neurological dysfunction |
| WO2015052105A1 (en) * | 2013-10-08 | 2015-04-16 | F. Hoffmann-La Roche Ag | Diazacarbazole derivatives as tau-pet-ligands |
Also Published As
| Publication number | Publication date |
|---|---|
| US12006316B2 (en) | 2024-06-11 |
| EA201791733A1 (ru) | 2018-01-31 |
| MY191590A (en) | 2022-06-30 |
| JP6579670B2 (ja) | 2019-09-25 |
| MX2017009505A (es) | 2017-11-02 |
| EP3253762B1 (en) | 2021-05-05 |
| US20220213103A1 (en) | 2022-07-07 |
| IL253381A0 (en) | 2017-09-28 |
| CN107207508A (zh) | 2017-09-26 |
| MX378155B (es) | 2025-03-10 |
| US20180022748A1 (en) | 2018-01-25 |
| WO2016124508A1 (en) | 2016-08-11 |
| IL253381B (en) | 2020-10-29 |
| KR20170113607A (ko) | 2017-10-12 |
| EA036518B1 (ru) | 2020-11-18 |
| BR112017016311A2 (pt) | 2018-03-27 |
| SG11201705727TA (en) | 2017-08-30 |
| AU2016214537A1 (en) | 2017-08-03 |
| CA2973648A1 (en) | 2016-08-11 |
| ES2875734T3 (es) | 2021-11-11 |
| JP2018503673A (ja) | 2018-02-08 |
| KR102621513B1 (ko) | 2024-01-04 |
| CA2973648C (en) | 2023-09-26 |
| US20210047326A1 (en) | 2021-02-18 |
| DK3253762T3 (da) | 2021-07-19 |
| EP3253762A1 (en) | 2017-12-13 |
| CN107207508B (zh) | 2020-02-28 |
| US11312716B2 (en) | 2022-04-26 |
| CL2017001923A1 (es) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12006316B2 (en) | 9H-pyrrolo-dipyridine derivatives | |
| JP6513107B2 (ja) | 神経原線維濃縮体のイメージング剤としてのピロロ［２，３−ｃ］ピリジン | |
| RU2645339C1 (ru) | Производные 1,5-нафтиридина и ингибиторы melk, содержащие их | |
| RS56315B2 (sr) | P2x7 modulatori | |
| KR20120007540A (ko) | ＰＩ3 키나제 및/또는 ｍＴＯＲ의 억제제 | |
| AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
| WO2019074809A1 (en) | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| CA3154247A1 (en) | N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| CN112912142B (zh) | 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物 | |
| JP7604067B2 (ja) | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 | |
| JP2024544245A (ja) | Ｔｙｋ２阻害剤の固体形態、調製方法、及びその使用 | |
| WO2024173219A1 (en) | Alpha-synuclein binders and methods of use | |
| EP4676547A2 (en) | Alpha-synuclein binders and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |